ESCRS - FP05.08 - Assessing The Impact Of European Group On Graves' Orbitopathy (Eugogo) Protocols On Intraocular Inflammation In Active Graves' Ophthalmopathy: A Quantitative Analysis Using Aqueous Flare Photometry

Assessing The Impact Of European Group On Graves' Orbitopathy (Eugogo) Protocols On Intraocular Inflammation In Active Graves' Ophthalmopathy: A Quantitative Analysis Using Aqueous Flare Photometry

Published 2024 - 42nd Congress of the ESCRS

Reference: FP05.08 | Type: Free paper | DOI: 10.82333/c08e-9089

Authors: Fatma Poslu Karademir 1 , Ilkay Semizoglu* 1 , Husna Topcu 1 , Ayse Cetin Efe 1 , Mehmet Goksel Ulas 1

1Ophthalmology,Beyoglu Eye Training and Research Hospital,Istanbul,Türkiye

Purpose

To quantitatively assess the impact of intravenous steroid treatment on intraocular inflammation in active Graves' ophthalmopathy through aqueous flare photometry, thereby evaluating the effectiveness of the European Group on Graves' Orbitopathy (EUGOGO) protocols.

Setting

This study was performed in the oculoplasty unit of Beyoglu Eye Training and Research Hospital

Methods

This study enrolled patients diagnosed with active Graves' ophthalmopathy, exhibiting a Clinical Activity Score (CAS) greater than 3. Adhering to EUGOGO protocols, participants received intravenous steroid treatments (0.5 g intravenous Methylprednisolone/week/ 6 weeks + Mycophenolate sodium 0.72 g/day/6 wk., in cases with a response, 0.25 g intravenous Methylprednisolone/wk./6 wk.+ Mycophenolate sodium 0.72 g/day/18 wk). Aqueous flare, indicative of intraocular inflammation, was quantitatively measured at baseline, after 6 weeks, and at the conclusion of 12 weeks of treatment using the FC-700 laser flare meter (Kowa Co. Ltd, Tokyo, Japan).

Results

The study included 11 patients (5 females and 6 males) with an average age of 46.0±11.0 years.   The mean CAS was 3.45±1.21 and the mean aqueous flare was 9.44±2.20 (ph/ms) before treatment. Six weeks after the start of steroid treatment, the mean CAS was 1.38±0.74 and the mean aqueous flare value was 6.07±2.03 (ph/ms). At the end of the treatment, the mean CAS was 0.63±0.74 and the mean aqueous flare was 4.15±0.94 (ph/ms). Comparing the pre-treatment, mid-treatment and post-treatment values, there was a significant decrease in CAS and aqueous flare values (all p<0.05).

Conclusions

The study's findings indicate that patients with active Graves' ophthalmopathy exhibit high levels of aqueous flare, which can be effectively reduced by following EUGOGO treatment protocols. This highlights the efficacy of the treatment protocol in managing intraocular inflammation and the potential of aqueous flare photometry as a valuable tool for monitoring treatment response.